| Name | Tetrac |
| Description | Tetrac (Tetraiodothyroacetic acid) is a derivative of L-thyroxine (T4), a thyroxine integrin receptor antagonist.Tetrac induces antiproliferation by blocking EGFR-mediated cell signaling in colorectal cancer cells.Tetrac blocks the effects of T4 and 3,5,3'-triiodo-L-thyronine (T3) on the cell-surface thyroxine integrin αvβ3 receptors.Tetra has anti-angiogenic, anti-tumor activity and pro-apoptotic activity. |
| In vitro | Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status, inhibits ERK1/2 activation (0.1 μM; 30 min), and modulates expression of CCND1, c-Myc, CASP2, and THBS1 (0.1 μM; 24 h), as demonstrated by cell proliferation assays in HT-29 and HCT116 cells[3]. |
| In vivo | Tetrac (35 μg/day; p.o.; for 40 days; Wild-type male Balb/C mice inoculated with 102B16F10 or B16LS9 cells) delayed the onset of ocular melanoma and reduced the S-100 and integrin staining levels. Tetrac can inhibit tumor inoculation, growth, and integrin expression in mice.[4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (334.3 mM), Sonication is recommended.
|
| Keywords | thyroxine | Tetrac | EGFR | Apoptosis |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Formamide | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Natural Product Library | Angiogenesis related Compound Library | Inhibitor Library | Natural Product Library for HTS | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
